{
    "body": "Which is the most important prognosis sub-classification in Chronic Lymphocytic Leukemia?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22560084", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16083281", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23468975", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20353875", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16014569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17786276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19500131", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16825496", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19127482"
    ], 
    "ideal_answer": [
        "The mutational status of the immunoglobulin heavy variable (IGHV) genes, defines two subsets: mutated and unmutated CLL. Unmutated CLL patients show a shorter progression-free and overall survival than mutated CLL patients."
    ], 
    "exact_answer": [
        "The mutational status of the IGHV genes."
    ], 
    "type": "factoid", 
    "id": "51739df58ed59a060a00001c", 
    "snippets": [
        {
            "offsetInBeginSection": 621, 
            "offsetInEndSection": 879, 
            "text": "One of the most reliable prognostic markers in chronic lymphocytic leukemia (CLL) is the mutational status of immunoglobulin heavy variable (IGHV) genes, which defines 2 subsets, mutated CLL (M-CLL) and unmutated CLL (U-CLL), with different clinical courses.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22560084", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 119, 
            "offsetInEndSection": 268, 
            "text": "Mutational status of the immunoglobulin heavy chain variable regions (IGHVs) of CLL cells offers useful prognostic information for high-risk patients", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 270, 
            "offsetInEndSection": 496, 
            "text": "but time and economical costs originally prevented it from being routinely used in a clinical setting. Instead, alternative markers of IGHV status, such as zeta-associated protein (ZAP70) or messenger RNA levels are often used", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20090781", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 109, 
            "offsetInEndSection": 282, 
            "text": "Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19127482", 
            "endSection": "sections.0"
        }
    ]
}